Facing COVID-19 in the Hematopoietic Cell Transplant Setting: A New Challenge for Transplantation Physicians

UMMS Affiliation

Department of Medicine, Division of Hematology and Oncology

Publication Date


Document Type

Letter to the Editor


Health Services Administration | Hematology | Hemic and Lymphatic Diseases | Infectious Disease | Neoplasms | Oncology | Virus Diseases


Coronavirus disease (COVID-19) Pandemic has put enormous pressure on the health care system worldwide. As of 8th April 2020, more than 220 countries are already affected with a total of 1,462,698 confirmed COVID-19 cases and 84,792 deaths across the globe [1]. Absence of a specific antiviral agent and vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has strangled the treating health care providers. The special population that is at high risk of acquiring SARS-CoV 2 infection are immunocompromised, and HIV infected persons, pregnant woman, and cancer patients [2]. We hereby discuss the challenges being faced by cancer patients, specifically the transplant recipients and their respective donors during COVID-19 pandemic. Transplantation societies are working closely to provide optimal support and recommendations to the transplant specialists to guide them to conduct hematopoietic cell transplantation (HCT) in the safest manner.


COVID-19, cancer, hematopoietic cell transplantation, HCT, blood donation

DOI of Published Version



Sahu KK, Jindal V, Siddiqui AD, Cerny J. Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians. Blood Cells Mol Dis. 2020 Apr 11;83:102439. doi: 10.1016/j.bcmd.2020.102439. Epub ahead of print. PMID: 32353701; PMCID: PMC7151275. Link to article on publisher's site

Journal/Book/Conference Title

Blood cells, molecules and diseases

Related Resources

Link to article in PubMed

PubMed ID